{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:38:23Z","timestamp":1763545103756,"version":"3.45.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-24077-1","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:25:58Z","timestamp":1763544358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of SARS-CoV-2 neutralizing antibody persistence using LFIC: a prevalence study after booster doses"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0647-0551","authenticated-orcid":false,"given":"Ana C.","family":"Montagud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0380-7910","authenticated-orcid":false,"given":"Ra\u00fal","family":"Moragues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6884-7572","authenticated-orcid":false,"given":"Eva Mar\u00eda","family":"Gabald\u00f3n-Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6363-2385","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Hurtado-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1159-429X","authenticated-orcid":false,"given":"Jos\u00e9","family":"Tuells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"15","key":"24077_CR1","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2101765.","journal-title":"N Engl J Med"},{"issue":"20","key":"24077_CR2","doi-asserted-by":"publisher","first-page":"10133","DOI":"10.26355\/eurrev_202310_34193","volume":"27","author":"SA Meo","year":"2023","unstructured":"Meo SA, Aftab S, Bayoumy NM, Meo AS. Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths. Eur Rev Med Pharmacol Sci. 2023;27(20):10133\u201343. https:\/\/doi.org\/10.26355\/eurrev_202310_34193.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"24077_CR3","unstructured":"Ministerio de Sanidad (Espa\u00f1a). Estrategia de vacunaci\u00f3n COVID-19 en Espa\u00f1a. Available online: https:\/\/www.sanidad.gob.es\/areas\/alertasEmergenciasSanitarias\/alertasActuales\/nCov\/vacunaCovid19.htm (accessed on 11 January 2024)."},{"issue":"4","key":"24077_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386(4):340\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2115481.","journal-title":"N Engl J Med"},{"issue":"10328","key":"24077_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(22)00152-0.","journal-title":"Lancet"},{"issue":"10327","key":"24077_CR6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S0140-6736(22)00089-7","volume":"399","author":"P Nordstr\u00f6m","year":"2022","unstructured":"Nordstr\u00f6m P, Ballin M, Nordstr\u00f6m A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399(10327):814\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(22)00089-7.","journal-title":"Lancet"},{"key":"24077_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41467-022-29225-4","volume":"13","author":"L P\u00e9rez-Al\u00f3s","year":"2022","unstructured":"P\u00e9rez-Al\u00f3s L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR, et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun. 2022;13:1614.","journal-title":"Nat Commun"},{"key":"24077_CR8","first-page":"e202312111","volume":"97","author":"AC Montagud","year":"2023","unstructured":"Montagud AC, Vicente-Alcalde N, Gabald\u00f3n-Bravo EM, Hurtado-S\u00e1nchez JA, Montagud E, Egoavil CM, et al. COVID-19 vaccination at the university of Alicante (Spain): detection of neutralizing antibodies against SARS-CoV-2 by rapid serological test, a cross-sectional study. Rev Esp Salud Publica. 2023;97:e202312111.","journal-title":"Rev Esp Salud Publica"},{"issue":"3","key":"24077_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.rce.2024.01.009","volume":"224","author":"AC Montagud","year":"2024","unstructured":"Montagud AC, Llenas-Garc\u00eda J, Moragues R, Perez-Bernabeu A, Alcocer-Pertegaz MJ, Garc\u00eda-G\u00f3mez FJ, et al. Prevalence of generated neutralizing antibodies against SARS-CoV-2 after two doses of BNT162b2 (Pfizer\u2013BioNTech) vaccine in health workers. Rev Clin Esp. 2024;224(3):28. https:\/\/doi.org\/10.1016\/j.rce.2024.01.009.","journal-title":"Rev Clin Esp"},{"issue":"4","key":"24077_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2313","volume":"32","author":"I Hadj Hassine","year":"2022","unstructured":"Hadj Hassine I. Covid-19 vaccines and variants of concern: a review. Rev Med Virol. 2022;32(4): e2313. https:\/\/doi.org\/10.1002\/rmv.2313.","journal-title":"Rev Med Virol"},{"key":"24077_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113522","volume":"154","author":"M Dhawan","year":"2022","unstructured":"Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: what do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother. 2022;154: 113522. https:\/\/doi.org\/10.1016\/j.biopha.2022.113522.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"24077_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202\u201321. https:\/\/doi.org\/10.1016\/j.cmi.2021.10.005.","journal-title":"Clin Microbiol Infect"},{"issue":"16","key":"24077_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2119451.","journal-title":"N Engl J Med"},{"key":"24077_CR14","unstructured":"de Sanidad M, Consumo y Bienestar Social (Espa\u00f1a). Comisi\u00f3n de Salud P\u00fablica tras revisi\u00f3n y propuesta realizada por la Ponencia de Programa y Registro de Vacunaciones junto con el Grupo de Trabajo T\u00e9cnico de Vacunaci\u00f3n COVID-19 y el Grupo de Trabajo de Vacunaci\u00f3n COVID-19 en la Poblaci\u00f3n Infantil. Actualizaci\u00f3n 10 - Estrategia de vacunaci\u00f3n frente a COVID-19 en Espa\u00f1a 2021. 27 de Febrero de 2021. Available: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/covid19\/Actualizaciones_Estrategia_Vacunacion\/docs\/COVID-19_Actualizacion10_EstrategiaVacunacion.pdf. Consulted on 29\/11\/2023."},{"key":"24077_CR15","unstructured":"de Sanidad M, Consumo y Bienestar Social (Espa\u00f1a). Comisi\u00f3n de Salud P\u00fablica tras revisi\u00f3n y propuesta realizada por la Ponencia de Programa y Registro de Vacunaciones junto con el Grupo de Trabajo T\u00e9cnico de Vacunaci\u00f3n COVID-19 y el Grupo de Trabajo de Vacunaci\u00f3n COVID-19 en la Poblaci\u00f3n Infantil. Actualizaci\u00f3n 11 - Estrategia de vacunaci\u00f3n frente a COVID-19 en Espa\u00f1a 2022. 2 de Febrero de 2022. Available: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/covid19\/Actualizaciones_Estrategia_Vacunacion\/docs\/COVID-19_Actualizacion11_EstrategiaVacunacion.pdf. Consulted on 29\/11\/2023."},{"key":"24077_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","volume":"27","author":"CR Simpson","year":"2021","unstructured":"Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021;27:1290\u20137. https:\/\/doi.org\/10.1038\/s41591-021-01408-4.","journal-title":"Nat Med"},{"issue":"20","key":"24077_CR17","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","volume":"386","author":"ED Moreira Jr","year":"2022","unstructured":"Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386(20):1910\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2200674.","journal-title":"N Engl J Med"},{"issue":"7","key":"24077_CR18","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1002\/jmv.27697","volume":"94","author":"S Chenchula","year":"2022","unstructured":"Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol. 2022;94(7):2969\u201376. https:\/\/doi.org\/10.1002\/jmv.27697.","journal-title":"J Med Virol"},{"issue":"4","key":"24077_CR19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40121-022-00652-6","volume":"11","author":"SM Hsieh","year":"2022","unstructured":"Hsieh SM, Chang SC, Cheng HY, Shih SR, Lien CE. Durability and immunogenicity of neutralizing antibodies response against Omicron variants after three doses of subunit SARS-CoV-2 vaccine MVC-COV1901: an extension to an open-label, dose-escalation phase 1 study. Infect Dis Ther. 2022;11(4):1493\u2013504. https:\/\/doi.org\/10.1007\/s40121-022-00652-6.","journal-title":"Infect Dis Ther"},{"key":"24077_CR20","doi-asserted-by":"publisher","first-page":"e069989","DOI":"10.1136\/bmj-2022-069989","volume":"377","author":"WY Au","year":"2022","unstructured":"Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022;377:e069989. https:\/\/doi.org\/10.1136\/bmj-2022-069989.","journal-title":"BMJ"},{"issue":"1","key":"24077_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-022-00977-x","volume":"11","author":"J Lv","year":"2022","unstructured":"Lv J, Wu H, Xu J, Liu J. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. Infect Dis Poverty. 2022;11(1): 53. https:\/\/doi.org\/10.1186\/s40249-022-00977-x.","journal-title":"Infect Dis Poverty"},{"issue":"6584","key":"24077_CR22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1126\/science.abn2688","volume":"375","author":"CI Kaku","year":"2022","unstructured":"Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, et al. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1\/mRNA-1273 vaccination. Science. 2022;375(6584):1041\u20137. https:\/\/doi.org\/10.1126\/science.abn2688.","journal-title":"Science"},{"issue":"1","key":"24077_CR23","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/s41467-022-30884-6","volume":"13","author":"T Patalon","year":"2022","unstructured":"Patalon T, Saciuk Y, Peretz A, Perez G, Lurie Y, Maor Y, Gazit S. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nat Commun. 2022;13(1):3203. https:\/\/doi.org\/10.1038\/s41467-022-30884-6. PMID: 35680872; PMCID: PMC9184525.","journal-title":"Nat Commun"},{"key":"24077_CR24","doi-asserted-by":"publisher","first-page":"6695533","DOI":"10.1155\/2023\/6695533","volume":"2023","author":"N Garg","year":"2023","unstructured":"Garg N, Kunamneni AS, Garg P, Sharma S, Sharma D, Kunamneni A. Antiviral drugs and vaccines for Omicron variant: A focused review. Can J Infect Dis Med Microbiol. 2023;2023:6695533. https:\/\/doi.org\/10.1155\/2023\/6695533.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"7","key":"24077_CR25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(23)00058-0","volume":"23","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly H, Ayoub HH, Tang P, Coyle P, Yassine HM, Al Thani AA, et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect Dis. 2023;23(7):816\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(23)00058-0.","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"24077_CR26","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","volume":"386","author":"YM Bar-On","year":"2022","unstructured":"Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022;386(18):1712\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2201570.","journal-title":"N Engl J Med"},{"key":"24077_CR27","unstructured":"Israeli Ministry of Health. Fourth Vaccine Dose. Available: https:\/\/corona.health.gov.il\/en\/vaccine-for-covid\/4th-dose\/. Consulted on 11\/01\/2024."},{"key":"24077_CR28","unstructured":"Food US, and Drugs Administration. Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for OlderImmunocompromised Individuals. FDA News Release. 2022. Available: https:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/310307c. Consulted on 11\/01\/2024."},{"key":"24077_CR29","unstructured":"Ministerio de Sanidad (Espa\u00f1a). Consejo Interterritorial Sistema Nacional de Salud. Recomendaciones de vacunaci\u00f3n frente a COVID-19 para el oto\u00f1o en Espa\u00f1a. Available online: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/covid19\/Historico_COVID-19\/docs\/Recomendaciones_vacunacion_Otono_Covid_VF.pdf. Consulted on 15\/02\/2024."},{"issue":"4","key":"24077_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18041908","volume":"18","author":"J Tuells","year":"2021","unstructured":"Tuells J, Egoavil CM, Pena Pardo MA, Montagud AC, Montagud E, Caballero P, et al. Seroprevalence study and cross-sectional survey on COVID-19 for a plan to reopen the university of Alicante (Spain). Int J Environ Res Public Health. 2021;18(4): 1908. https:\/\/doi.org\/10.3390\/ijerph18041908.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"24077_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cmi.2020.10.020","volume":"27","author":"A Rostami","year":"2021","unstructured":"Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(3):331\u201340. https:\/\/doi.org\/10.1016\/j.cmi.2020.10.020.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"24077_CR32","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1186\/s12889-022-13889-0","volume":"22","author":"KAS Davis","year":"2022","unstructured":"Davis KAS, Carr E, Leightley D, Vitiello V, Bergin-Cartwright G, Lavelle G, Wickersham A, Malim MH, Oetzmann C, Polling C, Stevelink SAM, Razavi R, Hotopf M. Indicators of recent COVID-19 infection status: findings from a large occupational cohort of staff and postgraduate research students from a UK university. BMC Public Health. 2022;22(1):1514. https:\/\/doi.org\/10.1186\/s12889-022-13889-0.","journal-title":"BMC Public Health"},{"issue":"4","key":"24077_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10040510","volume":"10","author":"J Tuells","year":"2022","unstructured":"Tuells J, Parra-Grande M, Santos-Calle FJ, Montagud AC, Egoavil CM, Garc\u00eda-Rivera C, et al. Detection of neutralizing antibodies against SARS-CoV-2 post-vaccination in health care workers of a large tertiary hospital in Spain by using a rapid test LFIC and sVNT-ELISA. Vaccines. 2022;10(4): 510. https:\/\/doi.org\/10.3390\/vaccines10040510.","journal-title":"Vaccines"},{"key":"24077_CR34","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.2147\/IJN.S408921","volume":"18","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liang J, Hu H, Wu M, Ma J, Ma Z, et al. Development of an effective neutralizing antibody assay for SARS-CoV-2 diagnosis. Int J Nanomed. 2023;18:3125\u201339. https:\/\/doi.org\/10.2147\/IJN.S408921.","journal-title":"Int J Nanomed"},{"issue":"12","key":"24077_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121376","volume":"9","author":"JJ Morales-N\u00fa\u00f1ez","year":"2021","unstructured":"Morales-N\u00fa\u00f1ez JJ, Mu\u00f1oz-Valle JF, Torres-Hern\u00e1ndez PC, Hern\u00e1ndez-Bello J. Overview of neutralizing antibodies and their potential in COVID-19. Vaccines. 2021;9(12): 1376. https:\/\/doi.org\/10.3390\/vaccines9121376.","journal-title":"Vaccines"},{"issue":"6","key":"24077_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11061125","volume":"11","author":"SM Abdalla","year":"2023","unstructured":"Abdalla SM, Mohamed EY, Elsabagh HM, Ahmad MS, Shaik RA, Mehta V, Mathur A, Ghatge SB. COVID-19 vaccine hesitancy among the general population: a cross-sectional study. Vaccines. 2023;11(6): 1125. https:\/\/doi.org\/10.3390\/vaccines11061125.","journal-title":"Vaccines"},{"issue":"1","key":"24077_CR37","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1186\/s12889-022-14225-2","volume":"22","author":"N Mongua-Rodr\u00edguez","year":"2022","unstructured":"Mongua-Rodr\u00edguez N, Rodr\u00edguez-\u00c1lvarez M, De-la-Rosa-Zamboni D, et al. Knowledge, attitudes, perceptions, and COVID-19 hesitancy in a large public university in Mexico City during the early vaccination rollout. BMC Public Health. 2022;22(1):1853. https:\/\/doi.org\/10.1186\/s12889-022-14225-2.","journal-title":"BMC Public Health"},{"issue":"5","key":"24077_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","volume":"23","author":"N Bobrovitz","year":"2023","unstructured":"Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the Omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556\u201367. https:\/\/doi.org\/10.1016\/S1473-3099(22)00801-5.","journal-title":"Lancet Infect Dis"},{"key":"24077_CR39","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.13.06004","volume":"13","author":"C Axfors","year":"2023","unstructured":"Axfors C, Pezzullo AM, Contopoulos-Ioannidis DG, Apostolatos A, Ioannidis JP. Differential COVID-19 infection rates in children, adults, and elderly: systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies. J Glob Health. 2023;13: 06004. https:\/\/doi.org\/10.7189\/jogh.13.06004.","journal-title":"J Glob Health"},{"issue":"13","key":"24077_CR40","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","volume":"386","author":"V Hall","year":"2022","unstructured":"Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2118691.","journal-title":"N Engl J Med"},{"issue":"1","key":"24077_CR41","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1186\/s12889-023-17239-6","volume":"23","author":"S Duong","year":"2023","unstructured":"Duong S, Burtniak J, Gretchen A, Mai A, Klassen P, Wei Y, Loeppky C, Shaw SY, Bullard J, Van Caeseele P, Stein DR. Riding high: Seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020-February 2022. BMC Public Health. 2023;23(1):2420. https:\/\/doi.org\/10.1186\/s12889-023-17239-6.","journal-title":"BMC Public Health"},{"key":"24077_CR42","unstructured":"Ministerio de Sanidad (Espa\u00f1a). Cuadro de mando resumen de datos de vacunaci\u00f3n. Available online: https:\/\/www.sanidad.gob.es\/areas\/alertasEmergenciasSanitarias\/alertasActuales\/nCov\/pbiVacunacion.htm. Consulted on 19\/23\/2024."},{"issue":"9","key":"24077_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091459","volume":"10","author":"AJ Roeder","year":"2022","unstructured":"Roeder AJ, Koehler MA, Jasbi P, McKechnie D, Vanderhoof J, Edwards BA, et al. Longitudinal comparison of neutralizing antibody responses to COVID-19 mRNA vaccines after second and third doses. Vaccines. 2022;10(9): 1459. https:\/\/doi.org\/10.3390\/vaccines10091459.","journal-title":"Vaccines"},{"key":"24077_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s43856-022-00151-2","volume":"2","author":"DF Lake","year":"2022","unstructured":"Lake DF, Roeder AJ, Gonzalez-Moa MJ, Koehler M, Kaleta E, Jasbi P, et al. Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders. Commun Med (Lond). 2022;2:85. https:\/\/doi.org\/10.1038\/s43856-022-00151-2.","journal-title":"Commun Med (Lond)"},{"issue":"11","key":"24077_CR45","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1002\/jmv.28026","volume":"94","author":"EJ Jang","year":"2022","unstructured":"Jang EJ, Choe YJ, Yun GW, Wang S, Cho UJ, Yi S, Lee S, Park YJ. Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study. J Med Virol. 2022;94(11):5589\u201392. https:\/\/doi.org\/10.1002\/jmv.28026.","journal-title":"J Med Virol"},{"key":"24077_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijid.2022.07.075","volume":"123","author":"M Almadhi","year":"2022","unstructured":"Almadhi M, Alsayyad AS, Conroy R, Atkin S, Awadhi AA, Al-Tawfiq JA, et al. Epidemiological assessment of SARS-CoV-2 reinfection. Int J Infect Dis. 2022;123:9\u201316. https:\/\/doi.org\/10.1016\/j.ijid.2022.07.075.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"24077_CR47","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/v14030640","volume":"14","author":"N Magazine","year":"2022","unstructured":"Magazine N, Zhang T, Wu Y, McGee MC, Veggiani G, Huang W. Mutations andEvolution of the SARS-CoV-2 Spike Protein\u00a0[published correction appears in Viruses. 2023;15(9)] Viruses. 2022;14(3):640.","journal-title":"Viruses"},{"issue":"7948","key":"24077_CR48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-022-05644-7","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2023;614(7948):521\u20139. https:\/\/doi.org\/10.1038\/s41586-022-05644-7.","journal-title":"Nature"},{"issue":"1","key":"24077_CR49","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1038\/s41467-022-35480-2","volume":"13","author":"M Canetti","year":"2023","unstructured":"Canetti M, Barda N, Gilboa M, Indenbaum V, Mandelboim M, Gonen T, et al. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up. Nat Commun. 2023;13(1):7711. https:\/\/doi.org\/10.1038\/s41467-022-35480-2.","journal-title":"Nat Commun"},{"issue":"5","key":"24077_CR50","doi-asserted-by":"publisher","first-page":"408","DOI":"10.37201\/req\/035.2021","volume":"34","author":"J Ruiz-Galiana","year":"2021","unstructured":"Ruiz-Galiana J, Cant\u00f3n R, De Lucas Ramos P, Garc\u00eda-Botella A, Garc\u00eda-Lled\u00f3 A, G\u00f3mez-Pav\u00f3n J, et al. Vacunaci\u00f3n anti-COVID-19: La Realidad Tras Los ensayos cl\u00ednicos [COVID-19 vaccination: the reality after clinical trials]. Rev Esp Quimioter. 2021;34(5):408\u201318. https:\/\/doi.org\/10.37201\/req\/035.2021.","journal-title":"Rev Esp Quimioter"},{"issue":"3","key":"24077_CR51","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/jmv.26539","volume":"93","author":"G Lippi","year":"2021","unstructured":"Lippi G, Mattiuzzi C. Clinical value of anti-SARS-COV-2 serum IgA titration in patients with COVID-19. J Med Virol. 2021;93(3):1210\u20131. https:\/\/doi.org\/10.1002\/jmv.26539.","journal-title":"J Med Virol"},{"issue":"25","key":"24077_CR52","doi-asserted-by":"publisher","first-page":"126184","DOI":"10.1016\/j.vaccine.2024.126184","volume":"42","author":"M Augello","year":"2024","unstructured":"Augello M, Wagenh\u00e4user I, Krone M, Dauby N, Ferrara P, Sabbatucci M, et al. Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment. Vaccine. 2024;42(25):126184. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126184.","journal-title":"Vaccine"},{"issue":"2","key":"24077_CR53","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.vaccine.2021.12.006","volume":"40","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2022;40(2):306\u201315. https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.006.","journal-title":"Vaccine"},{"issue":"1","key":"24077_CR54","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.jcvp.2022.100130","volume":"3","author":"L Dulipsingh","year":"2023","unstructured":"Dulipsingh L, Lang M, Diffenderfer MR, Cook L, Puff J, Diaz L, et al. Severe acute respiratory syndrome Corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination. J Clin Virol Plus. 2023;3(1):100130. https:\/\/doi.org\/10.1016\/j.jcvp.2022.100130.","journal-title":"J Clin Virol Plus"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24077-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-24077-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24077-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:26:01Z","timestamp":1763544361000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-24077-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24077"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-24077-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the University of Alicante (Spain) (File UA-2021-05-07_5, dated 24 May 2021), and the Department of Health, General University Hospital of Alicante (Spain) (File PI2021-094, Ref: 2021\u2009\u2212\u20090214, dated 30 June 2021). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4035"}}